GGrantIndex
← Leaderboards

Vicki L Traina-Dorge

Tulane University Of Louisiana

Google Scholar ↗PubMed ↗ORCID ↗
$5,386,412
Attributed
$5,627,725
Total exposure
36
Grants
20
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $835.2K · FY2005–25
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,627,725 · 36

By mechanism

R01$3,212,504 · 1
P51$1,932,594 · 34
R21$482,627 · 1

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Virus”

Research focus

VirusUnited States National Institutes Of HealthNonhuman PrimatePrimatesResourcesFundingGrantSourceInfectionChickenpoxMacaca MulattaComputer Retrieval Of Information On Scientific Projects DatabaseVaccinesInstitutionResearch PersonnelSimian VirusAnimalsViral Load ResultVirus DiseasesDoseCommunicable DiseasesImmunologyMammaliaImmunosuppressed

Grant awards (46)

Development of a Rhesus Macaque Model of Persistent Oral HPV and HIV Co-infection to Study Oropharyngeal Cancer Induction$209,987
R21 · FY2025 · DE · contact PI
Development of a Rhesus Macaque Model of Persistent Oral HPV and HIV Co-infection to Study Oropharyngeal Cancer Induction$272,640
R21 · FY2024 · DE · contact PI
Effect of immunization route and prior immunity for a live attenuated varicella AIDS vaccine$770,726
R01 · FY2019 · AI · contact PI
Effect of immunization route and prior immunity for a live attenuated varicella AIDS vaccine$799,482
R01 · FY2018 · AI · contact PI
Effect of immunization route and prior immunity for a live attenuated varicella AIDS vaccine$807,124
R01 · FY2017 · AI · contact PI
Effect of immunization route and prior immunity for a live attenuated varicella AIDS vaccine$835,172
R01 · FY2016 · AI · contact PI
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$57,750
P51 · FY2011 · RR · contact PI
IDENTIFICATION AND PRECLINICAL TESTING OF MICROBICIDES FOR HPV$37,186
P51 · FY2011 · RR · contact PI
MOLECULAR PATHOGENESIS OF VARICELLA ZOSTER VIRUS INFECTION$37,186
P51 · FY2011 · RR · contact PI
RESPIRATORY SYNCYTIAL VIRUS EFFICACY STUDY IN AFRICAN GREEN MONKEYS$61,801
P51 · FY2010 · RR · contact PI
IDENTIFICATION AND PRECLINICAL TESTING OF MICROBICIDES FOR HPV$61,801
P51 · FY2010 · RR · contact PI
MOLECULAR PATHOGENESIS OF VARICELLA ZOSTER VIRUS INFECTION$61,801
P51 · FY2010 · RR · contact PI
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$60,376
P51 · FY2009 · RR · contact PI
IDENTIFICATION AND PRECLINICAL TESTING OF MICROBICIDES FOR HPV$57,967
P51 · FY2009 · RR · contact PI
RESPIRATORY SYNCYTIAL VIRUS EFFICACY STUDY IN AFRICAN GREEN MONKEYS$57,967
P51 · FY2009 · RR · contact PI
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$57,967
P51 · FY2009 · RR · contact PI
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$64,630
P51 · FY2008 · RR · contact PI
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$24,103
P51 · FY2008 · RR · contact PI
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$30,391
P51 · FY2007 · RR · contact PI
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$30,391
P51 · FY2007 · RR · contact PI
MOLECULAR EPIDEMIOLOGY OF STLV-I IN WILD AND CAPTIVE SOOTY MANGABEYS$65,435
P51 · FY2006 · RR · contact PI
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$30,971
P51 · FY2006 · RR · contact PI
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$30,971
P51 · FY2006 · RR · contact PI
STLV-1 GENETIC DIVERSITY IN CAYO SANTIAGO RHESUS MACAQUES$30,971
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF REAL TIME PCR CORE LABORATORY$54,500
P51 · FY2005 · RR
MOLECULAR EPIDEMIOLOGY OF STLV-I IN WILD AND CAPTIVE SOOTY MANGABEYS$54,500
P51 · FY2005 · RR
ANIMAL MODELS TO DESIGN AND EVALUATE IMPROVED VZV VACCINES$37,662
P51 · FY2005 · RR
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$37,662
P51 · FY2005 · RR
EXPERIMENTAL STLV-I INFECTION AND STLV-1/SIV COINFECTION IN THE NONHUMAN PRIMATE$47,161
P51 · FY2004 · RR
MOLECULAR EPIDEMIOLOGY OF STLV-I IN MANGABEYS$47,161
P51 · FY2004 · RR
EVALUATION OF RECOMBINANT ATTENUATED RSV VACCINES$46,011
P51 · FY2004 · RR
ANIMAL MODELS TO DESIGN/EVALUATE IMPROVED VZV VACCINES$46,011
P51 · FY2004 · RR
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY$46,011
P51 · FY2004 · RR
EXPERIMENTAL STLV-I INFECTION AND STLV-1/SIV COINFECTION IN THE NONHUMAN PRIMATE$61,544
P51 · FY2003 · RR
SIMIAN VARICELLA VIRUS INFECTION AND LATENCY IN THE NONHUMAN PRIMATE$53,199
P51 · FY2003 · RR
EVALUATION OF RECOMBINANT ATTENUATED RSV VACCINES IN THE AFRICAN GREEN MONKEY$53,199
P51 · FY2003 · RR
ANTISENSE INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS IN THE NONHUMAN PRIMATE$53,199
P51 · FY2003 · RR
RHESUS MONKEY MODEL FOR HUMAN B19 PARVOVIRUS INFECT: HEMOLYTIC ANEMIA$0
P51 · FY2002 · RR
RSV VACCINE IMMUNOPOTENTIAT NON HUMAN PRIMATE MODEL: RESPIRATORY DISEASE$0
P51 · FY2002 · RR
MOLECULAR CHARACTERIZAT OF STLV I INDUCED TRANSFORMAT: CLONING &NUCLEOTIDE SEQ$0
P51 · FY2002 · RR
MOLECULAR CHARACTERIZAT OF STLV I INDUCED TRANSFORMAT: CLONING &NUCLEOTIDE SEQ$0
P51 · FY2001 · RR
RHESUS MONKEY MODEL FOR HUMAN B19 PARVOVIRUS INFECT: HEMOLYTIC ANEMIA$0
P51 · FY2001 · RR
RSV VACCINE IMMUNOPOTENTIAT NON HUMAN PRIMATE MODEL: RESPIRATORY DISEASE$0
P51 · FY2001 · RR
MOLECULAR CHARACTERIZATION OF SIV I INDUCED TRANSFORMATION$190,391
P51 · FY2000 · RR
INFANT NUTRITIONAL FORMULA FOR EFFICACY AGAINST RSV INFECTION IN RHESUS MONKEYS$190,391
P51 · FY2000 · RR
EFFECTS OF HTLV I COINFECTION ON SIV DISEASE$54,327
P51 · FY2000 · RR